The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.
Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA ...
Higher doses of Narcan — or naloxone — do not affect the possibility of survival after an overdose. Be cautious.
When I started taking opioids, they were all I was taking. I’d always thought of medicine as a take-only-when-needed kind of ...
Medical researchers have developed new non-opioid, non-addictive treatments for acute pain that are on pace to be approved by ...
LITTLE ROCK (KATV) — A new additional drug in the fight against the opioid overdose crisis has slowly been making its way across the country and it is now available right here in Arkansas, a ...
Some argue a need for more potent — and pricier — overdose reversal drugs; others frame that effort as drugmakers peddling ...
A group of 31 experts in genetics, addiction, psychiatry, and medical-device regulation sent letters to the FDA and Centers for Medicare and Medicaid Services, The Washington Post reported. The ...
The start of the opioid epidemic is ironically linked to a drug that was supposed to help people suffering from moderate to ...
Physicians said the test is based “on old genetic studies that have largely been abandoned” and could exacerbate the opioid crisis.
Purdue Pharma L.P. ("Purdue") announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*. If ...
Purdue Pharma has asked the federal Food and Drug Administration (FDA) to approve a new, auto-injectable form of one of its drugs to treat opioid overdoses. The Stamford-based biopharmaceutical ...